BC Partners is nearing a deal to sell Dutch generic drugmaker Synthon International Holding BV to Goldman Sachs Asset ...

BC Partners has agreed to sell its majority stake in Synthon to Goldman Sachs Alternatives. Synthon is an international pharmaceutical company, with a platform specialized in developing, manufacturing ...

Goldman Sachs Asset Management has agreed a more than €2bn deal to acquire drugmaker Synthon from BC Partners, according to people familiar with the matter, as it hopes to capitalise on demand for off ...

Goldman Sachs Asset Management (GS) is nearing a more than EUR 2B deal to buy drugmaker Synthon from BC Partners, people familiar tell the ...

Goldman Sachs Group Inc.’s alternative investment arm has agreed to buy a majority stake in Dutch generic drugmaker Synthon from BC Partners.

Goldman Sachs’ asset arm is in the process of acquiring the Dutch pharmaceutical company Synthon International for 2 billion ...

Bankers and direct lenders are going head-to-head to provide as much as €1 billion ($1.05 billion) of debt financing to help fund a potential sale of pharmaceutical firm Synthon, according to people ...

FB serves on the editorial boards of Brain, European Radiology, Neuroradiology, Neurology, Multiple Sclerosis Journal, and Radiology, serves as a consultant for Bayer-Schering Pharma, Sanofi-Aventis, ...

GG reports receiving fees for participation in the advisory board for AbbVie Biotherapeutics, Biogen, Canbex, Ironwood, Novartis, Merck, Inc, Merck Serono, Roche, Sanofi Genzyme, Synthon, Teva and ...

Dublin, Dec. 16, 2024 (GLOBE NEWSWIRE) -- The "Companion Diagnostic Collaboration and Licensing Deals 2010-2024" report has been added to ResearchAndMarkets.com's offering. Companion Diagnostic ...